This study is looking at whether tirzepatide, a medication given weekly, is a practical and acceptable treatment for postmenopausal women who have had hormone receptor-positive (HR+) breast cancer and also have obesity. Researchers want to see if participants are willing and able to take tirzepatide for 24 weeks (about 6 months), and if it helps with weight and overall health. You would have monthly check-ups. To join, you must be a woman aged 18 or older, postmenopausal, and have obesity (BMI of 30 or higher, or 27.5 or higher for Asian ancestry). The study aims to see how many participants complete all required assessments at 24 weeks. The current recruitment status is unclear.

Study design

This is an interventional study with 30 planned participants. It is exploring the use of tirzepatide in a specific group of women.

What's involved

You would take tirzepatide weekly for 24 weeks, with dose adjustments monthly. You would also have monthly check-ins, body composition assessments, blood tests, and provide a stool sample at the beginning and end of the study, along with completing surveys.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured at 24 weeks, indicating the duration of the study's active assessment period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.